Alternative dosing regimens for atezolizumab: right dose, wrong frequency Daniel A. GoldsteinMark J. Ratain Editorial 19 October 2019 Pages: 1153 - 1155
Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs Vinay SharmaSonu Kumar GuptaMalkhey Verma Review Article 04 September 2019 Pages: 1157 - 1166
A reliable method to determine which candidate chemotherapeutic drugs effectively inhibit tumor growth in patient-derived xenografts (PDX) in single mouse trials Derek GordonDavid E. Axelrod Original Article 12 September 2019 Pages: 1167 - 1178
A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics Floor J. E. LubbermanGuillemette E. BenoistNielka P. van Erp Original Article Open access 12 September 2019 Pages: 1179 - 1185
Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate Meng GaoDongjian ZhangFeng Wang Original Article 13 September 2019 Pages: 1187 - 1194
Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy Yanshuo CaoQing ChangEric X. Chen Original Article 13 September 2019 Pages: 1195 - 1200
Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial Thehang LuuPaul FrankelEdward M. Newman Original Article 14 September 2019 Pages: 1201 - 1208
Upregulation of miR-519 enhances radiosensitivity of esophageal squamous cell carcinoma trough targeting PI3K/AKT/mTOR signaling pathway Yanshan ZhangWeizuo ChenChao Li Original Article 16 September 2019 Pages: 1209 - 1218
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy Stefania CrucittaGiuliana RestanteRomano Danesi Original Article 16 September 2019 Pages: 1219 - 1227
ABCC11 gene polymorphism as a potential predictive biomarker for an oral 5-fluorouracil derivative drug S-1 treatment in non-small cell lung cancer Takehiro UemuraTetsuya OguriAkio Niimi Original Article 17 September 2019 Pages: 1229 - 1239
Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer Yuliang SunXiaoqian LinBrian R. Leyland-Jones Original Article 20 September 2019 Pages: 1241 - 1256
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting Kari M. MorrisseyMathilde MarchandRené Bruno Original Article Open access 21 September 2019 Pages: 1257 - 1267
JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer Takayuki YoshinoMasahito KotakaAtsushi Ohtsu Original Article Open access 23 September 2019 Pages: 1269 - 1277
BATF2 inhibits chemotherapy resistance by suppressing AP-1 in vincristine-resistant gastric cancer cells Wei YangSihui ZhaoRong Zeng Original Article 23 September 2019 Pages: 1279 - 1288
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies Leonard J. ApplemanJan H. BeumerSuresh S. Ramalingam Original Article 23 September 2019 Pages: 1289 - 1301
NO donor inhibits proliferation and induces apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells Ling LiuJingjing ChenShuying Wang Original Article 25 September 2019 Pages: 1303 - 1314
Combined thermo-chemotherapy of cancer using 1 MHz ultrasound waves and a cisplatin-loaded sonosensitizing nanoplatform: an in vivo study Rasoul IrajiradAmirhossein AhmadiAli Shakeri-Zadeh Original Article 26 September 2019 Pages: 1315 - 1321
A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors Mohammad Wasif SaifShrikar RajagopalRobert Martell Original Article 03 October 2019 Pages: 1323 - 1331
Cisplatin ototoxicity in children: risk factors and its relationship with polymorphisms of DNA repair genes ERCC1, ERCC2, and XRCC1 Caner TuranMehmet KantarTayfun Kirazlı Original Article 04 October 2019 Pages: 1333 - 1338
Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients Sonoko KawakatsuMina NikanjamEdmund V. Capparelli Original Article 04 October 2019 Pages: 1339 - 1348
Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial Ya ZhengJie ZhuHong Sun Clinical Trial Report 18 October 2019 Pages: 1349 - 1357
Prevalence of the DPYD variant (Y186C) in Brazilian individuals of African ancestry Geraldo Felício Cunha-JuniorLuciana Bastos-RodriguesLuiz Gonzaga Coelho Short Communication 22 October 2019 Pages: 1359 - 1363
Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial Fernando RiveraC. RomeroC. López Correction Open access 05 October 2019 Pages: 1365 - 1365